- Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
- Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan
- Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
- Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
- Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
- Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
- Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
- Coherus Completes Divestiture of Ophthalmology Franchise
- Coherus BioSciences Announces New Employment Inducement Grants
More ▼
Key statistics
On Friday, Coherus BioSciences Inc (CHRS:NMQ) closed at 2.12, 48.24% above the 52 week low of 1.43 set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.18 |
---|---|
High | 2.21 |
Low | 2.10 |
Bid | 2.12 |
Offer | 2.13 |
Previous close | 2.17 |
Average volume | 2.17m |
---|---|
Shares outstanding | 114.73m |
Free float | 110.09m |
P/E (TTM) | -- |
Market cap | 239.78m USD |
EPS (TTM) | -0.7801 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:15 BST.
More ▼